Núria Espinosa
About
Núria Espinosa is a scholar working on Infectious Diseases, Virology and Epidemiology.
According to data from OpenAlex, Núria Espinosa has authored 46 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Infectious Diseases, 16 papers in Virology and 16 papers in Epidemiology. Recurrent topics in Núria Espinosa's work include HIV/AIDS drug development and treatment (19 papers), HIV Research and Treatment (16 papers) and HIV/AIDS Research and Interventions (11 papers). Núria Espinosa is often cited by papers focused on HIV/AIDS drug development and treatment (19 papers), HIV Research and Treatment (16 papers) and HIV/AIDS Research and Interventions (11 papers). Núria Espinosa collaborates with scholars based in Spain, United States and United Kingdom. Núria Espinosa's co-authors include Luís F. López‐Cortés, Pompeyo Viciana, Alicia Gutiérrez‐Valencia, María Trujillo‐Rodríguez, Omar J. BenMarzouk‐Hidalgo, Karin Neukam, Beatriz Domínguez-Molina, P. Carrasco, N. Jornet and M. Ribas and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.
In The Last Decade
Núria Espinosa
44 papers receiving 357 citations
Peers
Núria Espinosa
Rafael Guerrero Spain
Alessandra Vergori Italy
Monika Bociąga‐Jasik Poland
Dilek Yıldız Sevgi Türkiye
Thérèse Staub Luxembourg
Hongyuan Liang China
Susan Orsega United States
Alexandra Scherrer Switzerland
Alfredo Scalzini Italy
Citations per year, relative to Núria Espinosa Núria Espinosa (= 1×)
peers
Rafael Guerrero
Countries citing papers authored by Núria Espinosa
Since
Specialization
Citations
This map shows the geographic impact of Núria Espinosa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Núria Espinosa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Núria Espinosa more than expected).
Fields of papers citing papers by Núria Espinosa
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Núria Espinosa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Núria Espinosa. The network helps show where Núria Espinosa may publish in the future.
Co-authorship network of co-authors of Núria Espinosa
This figure shows the co-authorship network connecting the top 25 collaborators of Núria Espinosa. A scholar is included among the top collaborators of Núria Espinosa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Núria Espinosa. Núria Espinosa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Montes, Marisa, Carmen Busca, Núria Espinosa, et al.. (2024). Incidence of Diabetes Mellitus and Associated Factors in the Era of Antiretroviral Drugs With a Low Metabolic Toxicity Profile. Open Forum Infectious Diseases. 11(4). ofae112–ofae112.
2.
Serna‐Gallego, Ana, María Trujillo‐Rodríguez, Núria Espinosa, et al.. (2024). Plasma concentrations of IL-6, MIP-1β, IP-10, and PTX-3 as predictors of the immunological response to antiretroviral treatment in people with HIV. Frontiers in Immunology. 15. 1447926–1447926.
3.
Serna‐Gallego, Ana, María Trujillo‐Rodríguez, Ana Isabel Álvarez‐Ríos, et al.. (2024). Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors. Frontiers in Immunology. 15. 1423734–1423734.
4.
López‐Cortés, Luís F., et al.. (2023). Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered. Frontiers in Immunology. 14. 1129753–1129753.
5.
Batterham, Rachel L., Núria Espinosa, Christine Katlama, et al.. (2023). Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens. Open Forum Infectious Diseases. 10(7). ofad359–ofad359.
6.
Serna‐Gallego, Ana, Luis Eduardo López-Cortés, María Trujillo‐Rodríguez, et al.. (2023). Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV. Journal of Antimicrobial Chemotherapy. 78(9). 2354–2360.
7.
Navarro, Jordi, Adrián Curran, Berta Raventós, et al.. (2023). Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain.. European Journal of Internal Medicine. 110. 54–61.
8.
Tarancón‐Díez, Laura, Beatriz Domínguez-Molina, Isabel Gallego, et al.. (2023). Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypes. EBioMedicine. 91. 104549–104549.
9.
Garcia, Dainelys, W. Andrew Rothenberg, Núria Espinosa, et al.. (2021). Rapid, Full-Scale Change to Virtual PCIT During the COVID-19 Pandemic: Implementation and Clinical Implications. Prevention Science. 22(3). 269–283.
10.
Asensio-Cruz, María Isabel, José Manuel Lomas, Cristina Roca-Oporto, et al.. (2021). Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Before–After Study (CortiCOVID Study). SHILAP Revista de lepidopterología. 3(2). 100086–100086.
11.
Ribas, M., et al.. (2019). Pseudo skin flash on VMAT in breast radiotherapy: Optimization of virtual bolus thickness and HU values. Physica Medica. 63. 56–62.
12.
Neukam, Karin, et al.. (2019). High-resolution anoscopy in HIV-infected men: Assessment of the learning curve and factors that improve the performance. Papillomavirus Research. 7. 62–66.
13.
Cuypers, Lize, Ana Belén Pérez, Natalia Chueca, et al.. (2018). Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis. PLoS ONE. 13(7). e0201268–e0201268.
14.
Teira, Ramón, Núria Espinosa, María Luisa Navarro Gómez, et al.. (2018). Pérdidas de seguimiento de personas con infección por el VIH en la cohorte española VACH en el periodo 2013-2014: importancia de los factores sociodemográficos. Enfermedades Infecciosas y Microbiología Clínica. 37(6). 361–366.
15.
Gutiérrez‐Valencia, Alicia, Coral García, Pompeyo Viciana, et al.. (2018). No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients. PLoS ONE. 13(9). e0203452–e0203452.
16.
López‐Cortés, Luís F., María Trujillo‐Rodríguez, Omar J. BenMarzouk‐Hidalgo, et al.. (2018). Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. The Journal of Infectious Diseases. 218(4). 624–632.
17.
Gutiérrez‐Valencia, Alicia, et al.. (2018). Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations. Journal of the International AIDS Society. 21(2).
18.
Gutiérrez‐Valencia, Alicia, et al.. (2018). Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment. PLoS ONE. 13(10). e0205777–e0205777.
19.
Neukam, Karin, Núria Espinosa, Antonio Collado, et al.. (2016). Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study. PLoS ONE. 11(5). e0155842–e0155842.
20.
Gutiérrez‐Valencia, Alicia, Rosa Ruiz-Valderas, Omar J. BenMarzouk‐Hidalgo, et al.. (2015). Telaprevir and Ribavirin Interaction: Higher Ribavirin Levels Are Not Only Due to Renal Dysfunction during Triple Therapy. Antimicrobial Agents and Chemotherapy. 59(6). 3257–3262.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rafael Guerrero Breakdown of academic impact, for papers by Alessandra Vergori Breakdown of academic impact, for papers by Monika Bociąga‐Jasik Breakdown of academic impact, for papers by Dilek Yıldız Sevgi Breakdown of academic impact, for papers by Thérèse Staub Breakdown of academic impact, for papers by Banafsheh Moradmand Badie Breakdown of academic impact, for papers by Hongyuan Liang Breakdown of academic impact, for papers by Susan Orsega Breakdown of academic impact, for papers by Alexandra Scherrer Breakdown of academic impact, for papers by Alfredo Scalzini